23andMe Holding Co. (MEUSW)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
23andMe Holding Co. (MEUSW) trades at $1.38 with AI Score 48/100 (Grade C). 23andMe Holding Co. is a consumer genetics and research company. They offer direct-to-consumer genetic testing and develop a genetic database for drug development. Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for MEUSW: MEUSW does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MEUSW against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
MEUSW: the 1 perspectives are evenly split.
How is this calculated? →23andMe Holding Co. (MEUSW) Healthcare & Pipeline Overview
23andMe Holding Co. is a consumer genetics and research company providing direct-to-consumer genetic testing and personalized genetic information. The company leverages a crowdsourced platform to build a comprehensive genetic database, aiming to accelerate drug discovery and offer insights into ancestry, traits, and health risks.
What Is the Investment Thesis for MEUSW?
Investing in 23andMe Holding Co. presents a unique opportunity in the consumer genetics and research space. The company's extensive genetic database is a valuable asset for drug discovery and personalized medicine. While the company's negative P/E ratio of -0.07 and a profit margin of -134.5% raise concerns about profitability, the gross margin of 53.3% indicates potential for improvement. Growth catalysts include expanding partnerships with pharmaceutical companies and increasing adoption of direct-to-consumer genetic testing. Key value drivers include the continued growth of the genetic database and successful development of new drug targets. Investors should monitor the company's progress in achieving profitability and managing regulatory risks.
Based on FMP financials and quantitative analysis
MEUSW Key Highlights
- Gross Margin of 53.3% indicates potential for profitability improvements.
- Focus on direct-to-consumer genetic testing provides a unique market position.
- Large genetic database offers opportunities for drug discovery and personalized medicine.
- Partnerships with pharmaceutical companies can drive revenue growth.
- Company incorporated in 2006 has established a presence in the consumer genetics market.
Who Are MEUSW's Competitors?
MEUSW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| PRE Prenetics Global Limited | $17.25 | +1.88% | $293.23M | 69 |
| EPGNY Epigenomics AG | $2.39 | +0.00% | 68 | |
| STRRP Star Equity Holdings, Inc. | $9.89 | -0.10% | $40.58M | 68 |
| TWST Twist Bioscience Corporation | $100.97 | +1.74% | $6.29B | 65 |
| CNTG Centogene N.V. | $0.33 | +100.00% | $9.42M | 50 |
| NVTA Invitae Corporation | $0.02 | -35.59% | $5.44M | 50 |
| ICLR ICON Public Limited Company | $170.94 | -1.23% | $13.09B | 50 |
| ME 23andMe Holding Co. | $0.61 | +100.00% | $15.31M | 50 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MEUSW's Key Strengths?
- Large and growing genetic database.
- Direct-to-consumer approach.
- Established brand recognition.
- Proprietary technology.
What Are MEUSW's Weaknesses?
- Negative profitability.
- High marketing expenses.
- Regulatory risks.
- Competition from established diagnostic companies.
What Could Drive MEUSW Stock Higher?
- Potential FDA approval for new genetic health risk reports.
- Expansion of partnerships with pharmaceutical companies for drug discovery.
- Increasing adoption of direct-to-consumer genetic testing services.
- Development of new personalized healthcare solutions.
What Are the Key Risks for MEUSW?
- Changes in regulations regarding genetic testing.
- Increasing competition from other consumer genetics companies.
- Data privacy and security breaches.
- Negative profitability and high marketing expenses.
- Dependence on consumer adoption of genetic testing.
What Are the Growth Opportunities for MEUSW?
- Expanding partnerships with pharmaceutical companies: 23andMe can leverage its extensive genetic database to collaborate with pharmaceutical companies in drug discovery and development. The market for genetic-based drug discovery is projected to reach billions of dollars in the coming years. These partnerships can provide significant revenue streams and accelerate the development of new therapies. Timeline: Ongoing.
- Increasing adoption of direct-to-consumer genetic testing: The market for direct-to-consumer genetic testing is growing as consumers become more aware of the potential benefits of personalized genetic information. 23andMe can capitalize on this trend by expanding its marketing efforts and offering new testing services. The global direct-to-consumer genetic testing market is expected to reach $2.5 billion by 2027. Timeline: Ongoing.
- Developing new personalized healthcare solutions: 23andMe can leverage its genetic database to develop personalized healthcare solutions tailored to individual genetic profiles. This includes offering personalized recommendations for diet, exercise, and lifestyle choices. The market for personalized healthcare is rapidly expanding, driven by advancements in genomics and data analytics. Timeline: Ongoing.
- Expanding into international markets: 23andMe can expand its geographic reach by entering new international markets. This includes offering its direct-to-consumer genetic testing services in countries with growing interest in personalized healthcare. The global market for genetic testing is expanding rapidly, particularly in emerging economies. Timeline: Ongoing.
- Leveraging AI and machine learning: 23andMe can leverage AI and machine learning technologies to analyze its vast genetic database and identify new drug targets and personalized healthcare solutions. AI-powered drug discovery is a rapidly growing field, with the potential to significantly accelerate the development of new therapies. Timeline: Ongoing.
What Opportunities Does MEUSW Have?
- Expanding partnerships with pharmaceutical companies.
- Increasing adoption of direct-to-consumer genetic testing.
- Developing new personalized healthcare solutions.
- Expanding into international markets.
What Threats Does MEUSW Face?
- Increasing competition.
- Changes in regulations.
- Data privacy concerns.
- Economic downturn.
What Are MEUSW's Competitive Advantages?
- Large and growing genetic database provides a competitive advantage.
- Direct-to-consumer approach allows for direct access to customers and data.
- Established brand recognition in the consumer genetics market.
- Proprietary technology and algorithms for analyzing genetic data.
What Does MEUSW Do?
23andMe, Inc., established in 2006 and headquartered in Sunnyvale, California, operates as a consumer genetics and research company. The company's mission is to help individuals access, understand, and benefit from the human genome. 23andMe provides direct-to-consumer genetic testing services, offering customers personalized information about their genetic predispositions to various health conditions, ancestry, and other traits. The company has built a substantial genetic database through its consumer testing services, which it leverages for research purposes, including drug discovery. 23andMe's platform allows users to contribute their genetic data for research, creating a crowdsourced approach to genetic studies. The company aims to unlock insights from this data to identify new drug targets and develop personalized healthcare solutions. 23andMe has an additional office in Mountain View, California. The company's business model focuses on both consumer services and research collaborations, positioning it at the intersection of personal genetics and pharmaceutical innovation.
What Products and Services Does MEUSW Offer?
- Provide direct-to-consumer genetic testing services.
- Offer personalized information about genetic health risks, ancestry, and traits.
- Develop a genetic database through crowdsourced contributions.
- Collaborate with pharmaceutical companies in drug discovery.
- Offer personalized healthcare solutions based on genetic profiles.
- Conduct research to identify new drug targets.
- Provide insights into the human genome.
How Does MEUSW Make Money?
- Generate revenue from direct-to-consumer genetic testing kits.
- Generate revenue from research collaborations with pharmaceutical companies.
- Potentially generate revenue from personalized healthcare solutions.
- Leverage a subscription model for ongoing access to updated genetic information and insights.
What Industry Does MEUSW Operate In?
The medical diagnostics and research industry is experiencing growth driven by advancements in genetic sequencing and personalized medicine. Companies like 23andMe are positioned to benefit from the increasing demand for genetic testing and the growing interest in personalized healthcare solutions. The competitive landscape includes established diagnostic companies, research institutions, and other consumer genetics providers. 23andMe differentiates itself through its direct-to-consumer approach and its focus on building a large, crowdsourced genetic database.
Who Are MEUSW's Key Customers?
- Individuals interested in learning about their ancestry and genetic traits.
- Individuals seeking personalized information about their health risks.
- Pharmaceutical companies seeking to identify new drug targets.
- Researchers studying the human genome.
Net buyingInsider Activity
The most recent 7 insider filings for 23andMe Holding Co. break down as 2 sales and 5 purchases. On net that is roughly 2.4M shares acquired (about $100K) — insiders putting money in tends to read as conviction.
MEUSW Valuation & Market Position
Relative to its peer group, MEUSW's quantitative score of 48/100 is below the peer average of 64/100.
Key Financial Metrics
Return on assets is -85.3%, showing how much profit it generates from its asset base. A current ratio of 0.81 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
23andMe Holding Co. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Sunnyvale, US. The company is led by CEO Anne Wojcicki. MEUSW has traded publicly since 2021.
MEUSW Financials
Bull Case vs Bear Case
Bull Case
- Large and growing genetic database.
- Direct-to-consumer approach.
- Established brand recognition.
- Proprietary technology.
Bear Case
- Negative profitability.
- High marketing expenses.
- Regulatory risks.
- Competition from established diagnostic companies.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
MEUSW Latest News
No recent news available for MEUSW.
MEUSW Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MEUSW.
Price Targets
Wall Street price target analysis for MEUSW.
MEUSW MoonshotScore
What does this score mean?
The MoonshotScore rates MEUSW's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Anne Wojcicki
CEO
Anne Wojcicki is the co-founder and CEO of 23andMe. She graduated from Yale University with a degree in biology. Prior to 23andMe, she worked as a healthcare analyst at various investment firms, including Passport Capital and Investor AB. Wojcicki has been recognized for her contributions to the field of genetics and personalized medicine.
Track Record: Under Anne Wojcicki's leadership, 23andMe has grown into a leading consumer genetics company. She has overseen the development of the company's direct-to-consumer genetic testing services and the expansion of its genetic database. Wojcicki has also led the company's efforts to collaborate with pharmaceutical companies in drug discovery.
23andMe Holding Co. Healthcare Stock: Key Questions Answered
What does 23andMe Holding Co. do?
23andMe Holding Co. is a consumer genetics and research company that provides direct-to-consumer genetic testing services. The company offers customers personalized information about their genetic predispositions to various health conditions, ancestry, and other traits. 23andMe also builds and maintains a large genetic database, which it leverages for research purposes, including drug discovery, collaborating with pharmaceutical companies to identify new drug targets and develop personalized healthcare solutions.
What do analysts say about MEUSW stock?
Analyst coverage of MEUSW stock is limited. Key valuation metrics, such as the P/E ratio, are currently negative due to the company's lack of profitability. Growth considerations include the company's ability to expand its genetic database, develop new partnerships, and achieve profitability. Investors should monitor the company's progress in these areas to assess its long-term potential. There is no consensus on whether to buy or sell the stock.
What are the main risks for MEUSW?
The main risks for 23andMe Holding Co. include regulatory risks related to genetic testing, increasing competition from other consumer genetics companies, and potential data privacy and security breaches. The company also faces challenges related to achieving profitability and managing its high marketing expenses. Dependence on consumer adoption of genetic testing is another significant risk factor. Investors should carefully consider these risks before investing in MEUSW stock.
How does 23andMe Holding Co. navigate regulatory approval processes?
23andMe Holding Co. has a history of working with the FDA to obtain regulatory clearance for its genetic health risk reports. The company has demonstrated a commitment to meeting regulatory requirements and ensuring the accuracy and reliability of its testing services. 23andMe continues to work with regulatory agencies to expand the scope of its approved tests and services. Investors should monitor the company's progress in obtaining regulatory approvals for new products and services.
What is 23andMe Holding Co.'s drug pipeline status?
23andMe Holding Co. does not have a traditional drug pipeline in the same way as pharmaceutical companies. Instead, it focuses on using its genetic database to identify potential drug targets and collaborate with pharmaceutical companies to develop new therapies. The company has partnerships with several pharmaceutical companies to advance drug discovery efforts in areas such as oncology and cardiovascular disease. Investors should monitor the progress of these partnerships and the potential for future revenue generation.
What are the key factors to evaluate for MEUSW?
23andMe Holding Co. (MEUSW) holds an AI score of 48/100 (low). Not financial advice.
How frequently does MEUSW data refresh on this page?
MEUSW prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven MEUSW's recent stock price performance?
23andMe Holding Co. (MEUSW) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Large and growing genetic database. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending may provide further insights.
- Limited analyst coverage may impact the accuracy of consensus estimates.